References

ACC. Illicit drug data report 2005-06, Australian Crime Commission, 2007.
Adlaf EM, Begin P, Sawka E. (eds.). Canadian Addiction Survey (CAS):
A national survey of Canadians’ use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa, Canadian Centre on Substance Abuse. 2005.
Aldy JE, Viscusi WK. Adjusting the value of a statistical life for age and cohort effects. The Review of Economics and Statistics, 2008, 90(3): 573-581.
Aos S, Phipps P, Barnoski R, Lieb R. The comparative costs and benefits of programs to reduce crime: A review of national research findings with implications for Washington State. Washington State Institute for Public Policy, Washington, D.C., 2001.
Australian Institute of Health and Welfare. Statistics on drug use in Australia 2006. Drug Statistics Series No. 18. Cat. no. PHE 80. Canberra, AIHW, 2007.
Australian Institute of Health and Welfare. 2007 National Drug Strategy Household Survey: first results. Drug Statistics Series number 20. Cat. no. PHE 98. Canberra, AIHW, 2008.
Barnett PG, Hui S. The Cost-Effectiveness of Methadone Maintenance. Mount Sinai Journal of Medicine,
October–November 2000, Vol. 67, Nos. 5–6: 365–374.
Bray JW, Zarkin GA, Ringwalt C, Qi J. The relationship between marijuana initiation and dropping out of High School. Health Economics, Vol. 9, No. 1, 2000b: 9–18.
Brown RE et al., Hepatitis B Management Costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol 38, no. 10 Suppl 3, 2004.
CCJS. Canadian Crime Statistics 2003. Canadian Centre for Justice Statistics, Catalogue no. 85-205-XIE. 2004.
Centers for Disease Control and Prevention. Surveillance for Acute Viral Hepatitis – United States, 2006. Surveillance Summaries. March 21, 2008. MMWR 2008;57(No. SS-2).
Collins DJ, Lapsley HM. Counting the cost: estimates of the social cost of drug abuse in Australia in 1998-9, National Drug Strategy Monograph Series No. 49, 2002.
Collins DJ, Lapsley HM. The costs of tobacco, alcohol and illicit drugs to Australian society in 2004/2005. National Drug Strategy Monograph Series No. 64. Canberra, Commonwealth Department of Health & Ageing, Canberra ACT Australia, 2008.
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). National report to the EMCDDA by the REITOX National Focal Point, Germany. Lisbon, EMCDDA, 2007.
EMCDDA. Statistical Bulletin, 2007. Problematic drug use population (PDU). 2007a.
Available: www.emcdda.europa.eu/stats07/PDU/methods, last accessed 24 February 2009.
EMCDDA. Towards a Better Understanding of Drug-related public expenditures. Lisbon, EMCDDA, 2008.
EMCDDA. Annual report on the state of the drug problem in Europe. Lisbon, EMCDDA, 2008a.
EMCDDA. Statistical Bulletin, 2008. Drug-related deaths. 2008b. Available: www.emcdda.europa.eu/stats08/drd/methods, last accessed 24 February 2009.
Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 34: 809-815, 2001.
French MT, Popovici I, Tapsell L. The economic costs of substance abuse treatment: Updated estimates and cost bands for policy and program evaluation. Unpublished manuscript. University of Miami, 2007.
French MT, Roebuck MC, Alexandre PK. Illicit drug use, employment and labor force participation. Southern Economic Journal, 2001, Vol. 68, No. 2: 349-368.
French MT, Zarkin GA. Is moderate alcohol use related to wages? Evidence from four worksites. Journal of Health Economics, August 1995, Vol. 14, No. 3: 319–344.
French MT, Zarkin GA, Dunlap LJ. Illicit drug use, absenteeism and earnings at six U.S. worksites. Contemporary Economic Policy, 1998, 16(3): 334-346.
Garcia-Altés A, Ollé JM, Antonanzas F, Colom J. The social cost of illegal drug consumption in Spain. Addiction 97, 2002: 1145-1153.
Godfrey, C. et al. The economic and social cost of a class drug use in England and Wales, Home Office Research Study 249, 2003. Available: www.homeoffice.gov.uk/rds/pdfs2/hors249.pdf, last accessed December 2008.
Gill AM, Michaels RJ. Does drug use lower wages? Industrial and Labour Relations Review, April 1992, Vol. 45, No. 3: 419–434.
Harwood H, Fountain D, Livermore, G. The economic costs of alcohol and drug abuse in the United States 1992. Rockville, MD: National Institutes on Drug Abuse, 1998.
Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a Quality-adjusted Life Year: In search of a standard. Medical Decision Making, 2000, 20: 332-342.
Hodgson TA, Meiners M. Guidelines for cost of illness studies in the Public Health Service: Task Force on cost of illness studies. Washington, DC, US Public Health Services, 1979.
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem.
Fund Q, 1982, 60: 429-462.
Hoyt G. Workplace substance use: Labour market outcomes and control policy. Presented at the Southern Economic Association Meetings, Washington, D.C., November 1992.
Kaestner R. The effect of illicit drug use on the wages of young adults. Journal of Labour Economics, October 1991, Vol. 9, No. 4: 381–412.
Kaestner R. New estimates of the effect of Marijuana and Cocaine use on wages. Industrial and Labour Relations Review, April 1994a, Vol. 47, No. 3: 454–470.
Kaestner R. The effects of illicit drug Use on the labour supply of young adults. Journal of Human Resources, Winter 1994b, Vol. 29, No. 1: 126–155.
Kaestner R. Drug use and AFDC participation: Is there a connection? Journal of Policy Analysis and Management, Summer 1998, Vol. 17, No. 3: 495–520.
Kilmer B, Pacula RL and Reuter P. Report 2: Estimating the size of the global drug market: A demand-side approach. Report for the European Commission. Brussels, 2009.
King JT, Joel T, Lave JR, Roberts MS. Willingness to pay for a Quality-Adjusted Life Year: Implications for societal health care resource allocation. Medical Decision Making, 2005, Volume 25: 667-677.
Kopp P, Fenoglio P. Public spending on drugs in the European Union during the 1990s. Lisbon, EMCDDA, 2003.
Krahn M et al., Costs and cost-effectiveness of a universal, school-based Hepatitis B vaccination program, Am J Public Health 1998, 88, no. 11.
Krentz HB, Auld MC, Gill MJ. The changing direct costs of medical care for patients with HIV/AIDS, 1995–2001. CMAJ, 22 July 2003, Vol. 169, No 2: 106–110.
Loubière S, Rotily M, Durand-Zaleski I, Costagliola D. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sanguinis, 2001, 80: 199-204.
MacCoun R, Reuter P and Schelling T. Assessing alternative drug control regimes. Journal of Policy Analysis and Management, 1996, 15(3): 330-352.
MacCoun R, Kilmer B, Reuter P. Research on drug-crime linkages: The next generation (commissioned paper). In: Toward a drugs and crime research agenda for the 21st century. National Institute of Justice Special Report, September 2003.
McCollister KE, French MT, Inciardi JA, Butzin CA, Martin SS and Hooper RM. Post-release substance abuse treatment for criminal offenders: A cost-effectiveness analysis. Journal of Quantitative Criminology, 2003, 19(4): 389-407.
National Institute of Justice. Arrestee Drug Abuse Monitoring Program (ADAM). Washington, D.C., U.S. Department of Justice, 2000.
Nicosia N, Pacula RL, Kilmer B, Lundberg R, Chiesa J. The economic cost of Methamphetamine use in the United States, 2005. MG-829 RAND. Santa Monica, RAND, 2009.
Office of National Drug Control Policy. The economic costs of drug abuse in the United States, 1992-2002. Washington, D.C.: Executive Office of the President (Publication No. 207303), 2004.
Postma M, Wiessing L and Jager J. Updated healthcare cost estimates for drug-related hepatitis C infections in the European Union, in Eds., 2004.
Postma M, Wiessing L and Jager J. Pharmaco-economics of drug addiction: estimating the costs of hepatitis c virus, hepatitis B virus and human inmmunodeficiency virus infection among injection drug users in Member States of the European Union, UN Bulletin on Narcotics, 2001, 53 (1/2): 79-89.
Public Health Agency of Canada. I-Track: Enhanced surveillance of risk behaviours among people who inject drugs. Phase I Report, August 2006. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2006.
Popova S, Rehm J, Patra J, Baliunas D, Taylor B. Illegal drug-attributable morbidity in Canada 2002. Drug and Alcohol Review, May 2007, 26: 251 – 263.
Pyne JM, French M, McCollister K, Tripathi S, Rapp R, Booth B. Preference-weighted health-related Quality of Life Measures and Substance Use Disorder Severity. Addiction, August 2008, Vol. 103, No. 8: 1320–1329.
Register CA, Williams DR. Labor Market effects of Marijuana and Cocaine use among young men. Industrial and Labour Relations Review, April 1992, Vol. 45, No. 3: 435–451.
Rehm J, Baliunas D, Brochu S, Fischer B, Gnam W, Patra J, Popova S, Hart A., Taylor B. The costs of substance abuse in Canada. Canadian Centre on Substance Abuse, Ottawa, ON. 2006.
Rigter H. What drug policies cost. Drug policy spending in the Netherlands in 2003. Addiction, 2006, 101(3): 323-329.
Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. 2005.
Seeff LB. Natural history of chronic hepatitis C. Hepatology, 2002, 36: S35-S46.
Shiell A, Law MG. The Cost of Hepatitis C and the Cost-Effectiveness of Its Prevention. Health Policy 2001, 58, no. 2.
TEDS (Treatment Episode Data Set). Annual data. Available: http://webapp.icpsr.umich.edu/cocoon/SAMHDA-SERIES/00056.xml, last accessed 23 February 2009.
Viscusi WK. The value of life: Estimates with risks by occupation and industry. Economic Inquiry, 2004, 42:1, 29–48.
Viscusi WK, Aldy JE. The value of a statistical life: A critical review of market estimates throughout the world. Journal of Risk and Uncertainty, 2003, 27: 5–76.
Wong JB. Hepatitis C: Cost of illness and economic considerations. Pharmacoeconomics, 2006, 24(7): 661-672.
Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am JPublic Health 2000, 90: 1100–11.
Zarkin GA, Dunlap LJ, Hicks KA and Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model, Health Economics 14, 2005: 1133-1150.
Zarkin GA, Mroz TA, Bray JW, French TM. The relationship between drug use and labour supply for young men, Labour Economics, December 1998, Vol. 5, No. 4: 385–409.